[ASSESSMENT OF INDICATORS FOR INTERFERON SYSTEM IN PATIENTS WITH COMMON FORMS OF PULMONARY TUBERCULOSIS RECEIVING COMPLEX THERAPY WITH CYCLOFERON].

We have evaluated the efficacy of cycloferon inclusion in the complex therapy of newly diagnosed patients with common forms of pulmonary tuberculosis, based on monitoring of the number of monocytes with receptors to interferon-gamma (flow cytometry) and the concentration of interferon-gamma in the serum (ELISA). For this purpose, a group of 36 patients (18 patients received standard chemotherapy, and 18 additionally received 600 mg cycloferon tablets 3 times per week) was examined for 3 months. Control group consisted of 18 apparently healthy patients.

[Meglumine acridonacetate and complex therapy of patients with newly identified advanced pulmonary tuberculosis].

Clinical and immunological efficacy of meglumine acridonacetate (cycloferon) tablets was evaluated in complex treatment of patients with newly diagnosed advanced pulmonary tuberculosis. It was shown that the use of cycloferon according to our scheme increased the efficacy of the therapy (earlier disappearance of the disease symptoms and bacteria isolation, shorter-terms of cavern healing, more pronounced positive radiographic dynamics vs. the patients under the etiotropic therapy).